Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cholinergic Modulation of Cognition and Emotion in Mood Disorders
NCT00055575Phase 2Terminated
- Sponsor
- National Institute of Mental Health
- Start
- Feb 2003
- Primary completion
- Feb 2015
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of scopolamine in major depressive disorder (MDD), bipolar disorder (BD), sponsored by National Institute of Mental Health. Started Feb 2003; status: terminated.
02
Drugs
scopolamine
03
Conditions
major depressive disorder (MDD)bipolar disorder (BD)
Beyond the preview
Go deeper on NCT00055575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00055575.